Change of adviser

RNS Number : 9068T

ReNeuron Group plc

23 March 2023

 

ReNeuron Group plc

("ReNeuron" or the "Company")

Change of adviser

ReNeuron Group plc (AIM: RENE) , a UK-based R&D organisation focused on exosome delivery technologies, announces the appointment of Allenby Capital Limited as the Company's Nominated Adviser and Sole Broker, with immediate effect.

ENDS

Enquiries:

ReNeuron	www.reneuron.com/investors
Iain Ross, Executive Chairman	Via Walbrook PR
John Hawkins, Chief Financial Officer
Allenby Capital Limited   (Nominated Adviser and Broker)	[phone]
James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR  (Media & Investor Relations)	[phone] or  [e-mail]
Paul McManus / Alice Woodings	[phone] / [phone]

About ReNeuron  

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects.  ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit  www.reneuron.com

 

END

 

 

APPELLFLXXLFBBZ